Healthcare
Zenas BioPharma, Inc.(ZBIO)
Live Price
Offline$18.58
+2.14% today
1Y Change
+96.20%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $960.00M
- Revenue Growth
- +100.0%
- EPS Growth
- -124.5%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zenas BioPharma, Inc. (ZBIO) is a Healthcare stock with a market cap of $960.00M and listed on NASDAQ. The stock last traded around $18.58 and up 96.2% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +100.0%, EPS growth of -124.5%, a dividend yield of 0.0%. What stands out right now is revenue +100.0%, EPS -124.5%, free cash flow -43.9% with operating margin -2163.8% and ROIC -67.2%. Valuation already assumes a fairly strong business story at price/sales 96.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ZBIO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+100.0% vs +7.6% peer median
Operating Margin
Below sector median
-2163.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +100.0% and EPS is at -124.5%, with operating margin around -2163.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.0% | +5.0% | +4.8% |
2026 Mar 16, 2026 | -272.1% | +1.1% | -11.2% | -8.1% |
2025 Nov 12, 2025 | -40.2% | -0.4% | +3.8% | +12.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZBIO
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZBIO Max Drawdown
-64.79%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZBIO and SPY.
Company Overview
Zenas BioPharma, Inc.
NASDAQ Global Select
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
- Leadership
- Leon Oliver Moulder Jr.
- IPO Date
- Sep 13, 2024
- Employees
- 130
- Street Address
- North Building
- Mailing
- Waltham, MA, 02451
- Region
- Waltham, MA, US
- Reporting Currency
- USD
- Investor Line
- (857) 271-2954
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 96.2
- Price/Book
- 4.1
Growth
- Revenue
- +100.0%
- EPS
- -124.5%
- Free Cash Flow
- -43.9%
Profitability
- Gross Margin
- -380.4%
- Operating Margin
- -2163.8%
- Net Margin
- -3777.4%
- ROE
- -157.0%
- ROIC
- -67.2%
Balance Sheet
- Debt/Equity
- 0.33
- Current Ratio
- 5.61
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.